Skip to content
Selzentry, Celsentri(maraviroc)
Celsentri, Selzentry (maraviroc) is a small molecule pharmaceutical. Maraviroc was first approved as Selzentry on 2007-08-06. It is used to treat HIV infections in the USA. It has been approved in Europe to treat HIV infections. The pharmaceutical is active against C-C chemokine receptor type 5.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
urogenital diseasesD000091642
immune system diseasesD007154
Trade Name
FDA
EMA
Selzentry (generic drugs available since 2022-02-07)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Maraviroc
Tradename
Company
Number
Date
Products
SELZENTRYViiV HealthcareN-022128 RX2007-08-06
4 products, RLD, RS
SELZENTRYViiV HealthcareN-208984 RX2016-11-04
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
selzentryNew Drug Application2022-11-30
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
hiv infectionsEFO_0000764D015658B20
Agency Specific
FDA
EMA
Expiration
Code
MARAVIROC, SELZENTRY, VIIV HLTHCARE
2024-04-30PED
2023-10-30NPP
Patent Expiration
No data
ATC Codes
J: Antiinfectives for systemic use
J05: Antivirals for systemic use
J05A: Direct acting antivirals
J05AX: Other antivirals in atc
J05AX09: Maraviroc
HCPCS
No data
Clinical
Clinical Trials
134 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hiv infectionsD015658EFO_0000764B2010131418959
HivD006678O98.74519624
Healthy volunteers/patients81110
Acquired immunodeficiency syndromeD000163EFO_0000765B202428
InflammationD007249112
Hiv-2D015498112
ProteinuriaD011507HP_0000093R8011
Heart disease risk factorsD00008274211
AtherosclerosisD050197EFO_0003914I25.111
Hepatitis cD006526B19.211
Show 2 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hiv-1D0154972316
StrokeD020521EFO_0000712I63.9313
Cardiovascular diseasesD002318EFO_0000319I98112
Aids dementia complexD015526EFO_0002608111
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Graft vs host diseaseD006086D89.81233
Covid-19D000086382U07.1123
Hematopoietic stem cell transplantationD018380122
Hematologic neoplasmsD019337122
B-cell chronic lymphocytic leukemiaD015451C91.111
Bcr-abl positive chronic myelogenous leukemiaD015464EFO_000034011
Hodgkin diseaseD006689C8111
Follicular lymphomaD008224C8211
Large b-cell lymphoma diffuseD016403C83.311
B-cell lymphomaD01639311
Show 4 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Colorectal neoplasmsD015179213
InfectionsD007239EFO_000054422
Pancreatic neoplasmsD010190EFO_0003860C2511
Mycobacterium avium complexD01526911
HypertriglyceridemiaD015228EFO_000421111
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Immune reconstitution inflammatory syndromeD054019D89.311
SarcoidosisD012507EFO_0000690D80-D8911
Neoplasm metastasisD009362EFO_000970811
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameMARAVIROC
INNmaraviroc
Description
Maraviroc is a monocarboxylic acid amide obtained by formal condensation of the carboxy group of 4,4-difluorocyclohexanecarboxylic acid and the primary amino group of (1S)-3-[(3-exo)-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]oct-8-yl]-1-phenylpropylamine. An antiretroviral drug, it prevents the interaction of HIV-1 gp120 and chemokine receptor 5 (CCR5) necessary for CCR5-tropic HIV-1 to enter cells. It has a role as an antiviral drug, a chemokine receptor 5 antagonist and a HIV fusion inhibitor. It is an azabicycloalkane, an organofluorine compound, a member of triazoles and a monocarboxylic acid amide.
Classification
Small molecule
Drug classantivirals; antivirals, chemokine receptor (CCR) antagonists
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
Cc1nnc(C(C)C)n1[C@H]1C[C@@H]2CC[C@H](C1)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)c1ccccc1
Identifiers
PDB4MBS
CAS-ID376348-65-1
RxCUI620216
ChEMBL IDCHEMBL1201187
ChEBI ID63608
PubChem CID3002977
DrugBankDB04835
UNII IDMD6P741W8A (ChemIDplus, GSRS)
Target
Agency Approved
CCR5
CCR5
Organism
Homo sapiens
Gene name
CCR5
Gene synonyms
CMKBR5
NCBI Gene ID
Protein name
C-C chemokine receptor type 5
Protein synonyms
C-C motif chemokine receptor 5 A159A, CD195, chemokine (C-C motif) receptor 5, chemokine receptor CCR5, chemokine recptor CCR5 Delta32, CHEMR13, HIV-1 fusion coreceptor, mutant C-C motif chemokine receptor
Uniprot ID
Mouse ortholog
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 5,639 documents
View more details
Safety
Black-box Warning
Black-box warning for: Selzentry
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
726 adverse events reported
View more details